Senior Cybersecurity Engineer
SchrödingerSalary not specified
- Full Time
- Senior (5 to 8 years)
About Schrödinger
Schrödinger provides a computational platform that aids in the research efforts of biopharmaceutical companies, academic institutions, and government laboratories around the world. Their platform offers advanced computational tools that help in drug discovery and development across various therapeutic areas. Schrödinger's products work by using sophisticated algorithms and simulations to predict how different compounds will interact, which can significantly speed up the research process. Unlike many competitors, Schrödinger not only licenses its software but also engages in collaborative research and drug discovery programs, allowing for a more integrated approach to scientific research. The company's goal is to enhance scientific research and development through its platform, ultimately leading to the discovery of new drugs and therapies.
New York City, New YorkHeadquarters
1990Year Founded
$362.7MTotal Funding
IPOCompany Stage
Government & Public Sector, Enterprise Software, BiotechnologyIndustries
501-1,000Employees
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Company Match
401(k) Retirement Plan
Flexible Work Hours
Remote Work Options
Paid Vacation
Parental Leave
Risks
Recursion and Exscientia merger creates strong AI-driven drug discovery competitor.
Avicenna's independent expansion could lead to competitive tensions with Schrödinger.
High R&D costs may strain resources despite Gates Foundation's $10M grant.
Differentiation
Schrödinger's platform supports diverse clients, including biopharma, academia, and government labs.
The company excels in rapid drug discovery, exemplified by SGR-1505's swift development.
Schrödinger's collaboration with Avicenna enhances medicinal chemistry through machine learning.
Upsides
$19.5M Gates Foundation grant boosts platform for neglected diseases, expanding market reach.
Predictive toxicology tools initiative could lead to safer, efficient drug development.
SGR-1505 discovery showcases ability to reduce drug discovery timelines significantly.
Funding
Total raised$362.73 M
Latest valuation$550.00 M
StageIPO
GRANT
6/30/2024$10
POST IPO EQUITY
7/31/2020$346
IPO
1/31/2020$232
SERIES F
4/30/2019$110
$550.00 MSERIES E
12/31/2018$85
$425.00 MLATE VC
10/31/2018$80
$400.00 MGROWTH EQUITY VC
5/31/2015$22
$187.00 MSERIES A
2/28/2002$31
$155.00 M